hrs4r
 I want to donate
Firma
ÈLIA SAIS-GIRONA
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1

Projectes

Codi oficial: La Marató 201906-30 Start date:30/09/2020 Data fi: 29/09/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 109,562.50 €

Publicacions

0

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8

Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164168

Bosch-Barrera J, Oliva E, Sais E, Vásquez CA, Roselló A, Menéndez JA

Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.

ANTI-CANCER DRUGS, 2019, 30, 1067-1070 dx.doi.org/10.1097/CAD.0000000000000837

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Oncotarget, 2019, 10, 2576-2576 dx.doi.org/10.18632/oncotarget.26855

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2018, 9, 33043-33049 dx.doi.org/10.18632/oncotarget.25984

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R

Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Oncotarget, 2018, 9, 27074-27086 dx.doi.org/10.18632/oncotarget.25478

López Brunsó M, Toro Blanch C, Sais Girona E, Roa García D, Hernández Martínez A, Izquierdo Font A, Guerra Prió S, Mas Pueyo HG, Bosch-Barrera J

Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer.

ANTI-CANCER DRUGS, 2018, 29, 380-383 dx.doi.org/10.1097/CAD.0000000000000600

Formulari de contacte

About IDIBGI!

menu